This study supports the concept that increasing expression of FOXF1 or its downstream target FZD4 in tumor endothelial cells, either pharmacologically or via gene therapy, can be considered for NSCLC treatment. This evidence concerns the gene FOXF1 and non-small cell lung carcinoma.